Histamine H1 receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Histamine H1 receptor as ChEMBL target CHEMBL4701, mapped to UniProt P31390. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Histamine H1 receptor matters
Histamine H1 receptor is reviewed as Histamine H1 receptor (UniProt P31390); the current evidence base includes 29 approved drugs, 208 compounds, and 68 assays, with lead potency reaching pChEMBL 10.7.
Histamine H1 receptor Sequence length is 486 aa.
Review this target as Histamine H1 receptor, mapped to UniProt P31390. Sequence length is 486 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 29 approved drugs, 208 compounds, and 68 assays for this target. The dominant activity type is KI. CHEMBL629 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL629 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Histamine H1 receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P31390, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL629
|
10.7 | IC50 | Approved |
|
|
No preferred name
CHEMBL445
|
10.3 | IC50 | Approved |
|
|
No preferred name
CHEMBL11
|
10.2 | IC50 | Approved |
|
|
No preferred name
CHEMBL415
|
9.7 | IC50 | Approved |
|
|
No preferred name
CHEMBL715
|
9.5 | Ki | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
LORATADINE
CHEMBL998
|
1993 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
AZATADINE
CHEMBL946
|
1977 |
|
|
LOXAPINE
CHEMBL831
|
1975 |
|
|
PYRILAMINE
CHEMBL511
|
1973 |
|
|
CHLORPROTHIXENE
CHEMBL908
|
1967 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
DESIPRAMINE
CHEMBL72
|
1964 |
|
|
NORTRIPTYLINE
CHEMBL445
|
1964 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
|
|
IMIPRAMINE
CHEMBL11
|
1959 |
|
|
ORPHENADRINE
CHEMBL900
|
1957 |
|
|
PROMETHAZINE
CHEMBL643
|
1951 |
|
|
CHLORPHENIRAMINE
CHEMBL505
|
1950 |
|
|
HISTAMINE
CHEMBL90
|
1939 |